The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model
Pradelli L, Iannazzo S, Zaniolo O. – Am J Cardiovasc Drugs 2009; 9: 383-392
Effectiveness and cost of treatment with maraviroc in HIV infection
Sacchi V, Pradelli L. – Farmeconomia e percorsi terapeutici 2009; 10(4): 149-159
Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery
Zaniolo O. – Farmeconomia e percorsi terapeutici 2009; 10(3): 115-128
Sugammadex in antagonism of neuromuscular block in anesthesia: a clinical and economic profile
Sacchi V, Iannazzo S, Giunta F. – Farmeconomia e percorsi terapeutici 2009; 10(3): 103-114
The clinical and economic value of the dipeptide alanyl-glutamine in total parenteral nutrition of critically ill patients treated in intensive care units in Italy
Muscaritoli M, Pradelli L, Zaniolo O, Iannazzo S, Eandi M. – Farmeconomia e percorsi terapeutici 2009; 10(2): 83-92
Costs of diabetes in Italy
Zaniolo O. – Farmeconomia e percorsi terapeutici 2009; 10(2): 73-81
Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy
Iannazzo S, Sacchi V. – Farmeconomia e percorsi terapeutici 2009; 10(2): 59-72
Solifenacin in the treatment of overactive bladder syndrome in italian patients: pharmacoeconomic evaluation
Pradelli L, Iannazzo S. – Journal of Medical Economics 2009; 12(1): 25-35
Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy
Bamfi F, Basso F, Aglietta M, Bengala C, Lorusso V, Pronzato P, Cavallo MC, Zaniolo O, Iannazzo S. – Farmeconomia e percorsi terapeutici 2009; 10(1): 33-46
Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
Benucci M, Iannazzo S, Sabadini L. – Farmeconomia e percorsi terapeutici 2009; 10(1): 19-31
Budget impact analysis of use of aliskiren in hypertension on the italian health care system
Zaniolo O, Pradelli L. – Farmeconomia e percorsi terapeutici 2009; 10(1): 5-18
